Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
20.41M | 34.16M | 59.08M | 34.75M | 23.27M | 18.32M | Gross Profit |
4.42M | 34.16M | 42.83M | 19.78M | 23.27M | 18.32M | EBIT |
-79.79M | -69.42M | -26.65M | -35.61M | -25.62M | -13.03M | EBITDA |
-62.60M | -49.73M | -13.01M | -19.38M | -10.59M | -2.11M | Net Income Common Stockholders |
-63.02M | -50.62M | -22.33M | -27.04M | -17.56M | -13.59M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
86.98M | 86.98M | 88.27M | -13.85M | -2.59M | 0.00 | Total Assets |
401.99M | 375.23M | 421.21M | 304.46M | 295.38M | 262.32M | Total Debt |
25.56M | 25.56M | 25.80M | 13.85M | 2.59M | 2.27M | Net Debt |
9.20M | 9.20M | -7.59M | 27.70M | 5.18M | 2.27M | Total Liabilities |
87.40M | 60.64M | 79.84M | 70.16M | 59.84M | 44.13M | Stockholders Equity |
314.58M | 314.58M | 341.37M | 234.31M | 235.54M | 218.19M |
Cash Flow | Free Cash Flow | ||||
-108.61M | 703.00K | -20.75M | -9.74M | 1.87M | -5.45M | Operating Cash Flow |
-105.23M | 2.35M | -3.59M | -5.67M | 3.62M | -5.20M | Investing Cash Flow |
112.45M | -18.38M | -73.31M | -4.03M | -26.98M | -12.10M | Financing Cash Flow |
8.68M | -892.00K | 110.74M | 9.70M | 23.36M | 17.29M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $268.27M | ― | -36.07% | ― | ― | -7.93% | |
51 Neutral | $5.32B | 3.41 | -40.36% | 2.89% | 17.93% | 2.52% | |
50 Neutral | $214.96M | ― | -20.60% | ― | -22.75% | -19.65% | |
45 Neutral | $223.37M | ― | 239.90% | ― | ― | -17.92% | |
44 Neutral | $386.17M | ― | -526.33% | ― | ― | 14.39% | |
43 Neutral | $288.54M | ― | -16.20% | ― | 498.72% | 49.92% | |
33 Underperform | $235.23M | ― | -139.56% | ― | ― | -33.79% |
On April 18, 2025, OmniAb, Inc. appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. as Class II directors to its Board, with terms expiring in 2027. Mr. Crouse, with over 20 years of experience in life sciences, joins the Audit and Science and Technology Committees, while Dr. Gotwals, with 30 years in biopharmaceuticals, joins the Human Capital Management and Compensation and Science and Technology Committees. Both were granted restricted stock units and options as part of their compensation. Concurrently, Sarah Boyce resigned from the Board, which expanded from six to seven members.
Spark’s Take on OABI Stock
According to Spark, TipRanks’ AI Analyst, OABI is a Neutral.
OmniAb is facing significant financial challenges with declining revenues and persistent losses. While the company shows potential through its strong pipeline and growth in partnerships, these positives are offset by technical indicators suggesting bearish momentum. The valuation is unattractive due to the negative P/E ratio and lack of dividends. Overall, the stock’s score reflects these mixed signals, with financial performance being the most significant factor.
To see Spark’s full report on OABI stock, click here.